BSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,175.50
- Market cap
- ₹1,18,283 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.2×Sector 46.1×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Capacity Expansion: ₹190 Cr Investment
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.
- Value
- ₹190.0 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences presented post-hoc analysis from its EPICS-III clinical trial for Saroglitazar at ACG 2026. The drug remains under regulatory review for PBC treatment.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited submitted the quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming share dematerialization compliance for the quarter ended September 30, 2026.
Other board meeting date announcements
All →M M Forgings Board Meeting Date
MM Forgings scheduled its Q2 FY27 board meeting for 5 November 2026 to approve unaudited standalone and consolidated results for the quarter ended 30 September 2026.
Gujarat Terce Laboratories Board Meeting Date
Gujarat Terce Laboratories will hold a board meeting on November 5, 2026 to consider unaudited standalone results for September 2026. The trading window stays closed until November 7, 2026.
Gautam Gems Board Meeting Date
Gautam Gems Ltd scheduled a board meeting for 3 Nov 2026 to approve Q2 FY27 standalone results. No financial figures or other material decisions are disclosed in this advance intimation.
Gujjubhai Industries Board Meeting Date
Gujjubhai Industries has scheduled its Board meeting for 4 November 2026. The agenda includes approval of unaudited Q1 and H1 FY27 financial results.
The Hi-Tech Gears Board Meeting Date
The Hi-Tech Gears Ltd has scheduled a Board meeting on November 4, 2026 to approve un-audited Q1 and H1 FY27 results. No financial figures are disclosed.
Cranex Board Meeting Date
Cranex Ltd scheduled a board meeting for 5 Nov 2026 to consider Q2 FY27 financial results. No monetary figures or decisions are disclosed in this advance notice.